不同斑块形态中的药物涂层气球PCI:叙述性审查
Flavius-Alexandru Gherasie1,2, Raluca Ciomag Ianula1,2, Luana-Maria Gherasie3
1Department of Cardiology, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.
Biomedicines
|June 26, 2025
概括
药物涂层气球 (DCB) 为冠状动脉疾病提供了无支架的选择. 涂上西罗利木斯的气球 (SCBs) 是有前途的,在各种损伤类型中,其结果与涂上帕克利塔塞尔的气球 (PCBs) 相似.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
背景情况:
- 药物涂层气球 (DCBs) 代表了穿皮冠状动脉干预 (PCI) 的进步,为冠状动脉疾病提供了无支架的替代方案.
- 帕克利塔克塞尔涂层气球 (PCB) 已成为既定标准,但西洛利木斯涂层气球 (SCB) 正在出现,具有独特的药理动力学和临床优势.
研究的目的:
- 在DCB中审查帕克利塔塞尔和西洛利木斯的作用机制.
- 分析这些剂对各种斑块形态的影响.
- 讨论在个性化PCI策略中对DCB选择的临床影响.
主要方法:
- 一个叙事评论,综合从全面的文献搜索中获得的证据.
- 搜索的数据库包括PubMed和MEDLINE.
- 选择了相关研究,包括随机对照试验,注册表和元分析.
主要成果:
- 帕克利塔塞尔在纤维化和富含脂质的斑块中有效,但在化病变中是有限的.
- 西洛利斯在不稳定,富含脂质和炎症性斑块中表现出有效性,促进稳定.
- 最近的试验显示,SCB与PCB在新生病变和静脉静脉复缩中具有非劣质的结果.
结论:
- 在小血管疾病中,DCBs的疗效与药物排泄支架 (DES) 相同,可能减少对金属支架的需求.
- 在选择DCB时,应考虑个性化PCI的斑块特性.
- 需要进一步的研究来优化使用DCB技术的个性化PCI策略.
关键词:
冠状动脉疾病是一种冠状动脉疾病.在新增的病变中.用药物涂层的气球.在静脉支架内恢复缩.用帕克利塔塞尔涂层的气球通过皮肤进行冠状动脉干预.斑块形态学 斑块形态学用西罗利斯涂覆的气球血管改造 血管改造 血管改造更多相关视频
09:36A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis
Published on: August 12, 2025
100
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
4.1K
相关概念视频
01:27Peripheral Artery Disease III: Interprofessional Care
34
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
34
01:27Coronary Artery Disease V: Interprofessional Care
39
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
39
01:26Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
655
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
655
01:26Coronary Artery Disease II: Pathophysiology
42
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
42
01:26Angina IV: Management
31
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
31